Vaccination efforts continue despite the majority of the population completing the vaccination schedule in most regions of the world. Deaths and serious diseases prevented by vaccines are undeniable, but the delta variant has identified the risky age group as young people, and the worries are not completely over. This is one of the most important issues on the agenda of scientists lately.
It is known that COVID-19 can cause enough problems for 1 in 10 babies to be hospitalized. Although children are luckier against COVID-19, there are also severely ill cases and deaths. That’s why scientists have been discussing for some time whether it would be okay to lower the age at which vaccines can be administered. A vaccine company has recently taken one of the most important steps in this regard by asking permission for the vaccine to be administered to children over the age of 5 in the USA.
The tests were successful:
The increased likelihood of children catching the virus due to the mutations of COVID-19 has exacerbated concerns with the opening of schools. Many vaccine manufacturers have on the agenda to find out whether their vaccines can be administered to young children and, if the result is positive, to obtain the necessary permits. The US company Pfizer, which produces COVID-19 vaccines in partnership with BioNTech, has requested emergency use approval in order for the vaccine to be administered to children aged 5-11 in the USA.
In a news we shared recently, we mentioned that experiments with the Pfizer/BioNTech vaccine revealed that the vaccine was safe to be administered to children aged 5-11. In tests, it was revealed that children who received a dose of 1/3 that applied to adults produced the same amount of antibodies as the same adults. In addition, in the experiments carried out on 2,268 participants, it was determined that the children tolerated the vaccine well and did not cause any physical problems.
57919
